Our laboratory has focused on finding novel Alzheimer disease (AD) biomarkers or biomarker combinations associated with amyloid plaques, neurofibrillary tangles, brain atrophy, cognitive decline, and clinical dementia symptoms. Staging AD with a combination of biomarkers has been a major focus. The lab has been particularly interested in blood-based biomarkers, which have been rapid developing. The lab is committed to performing research that identifies and reduces health care disparities.
Featured publications
Acceptable performance of blood biomarker tests of amyloid pathology – recommendations from the Global CEO Initiative on Alzheimer’s Disease
July 1, 2024
Schindler SE, Galasko D, Pereira AC, Rabinovici GD, Salloway S, Suárez-Calvet M, Khachaturian AS, Mielke MM, Udeh-Momoh C, Weiss J, Batrla R, Bozeat S, Dwyer JR, Holzapfel D, Jones DR, Murray JF, Partrick KA, Scholler E, Vradenburg G, Young D, Algeciras-Schimnich A, Aubrecht J, Braunstein JB, Hendrix J, Hu YH, Mattke S, Monane M, Reilly D, Somers E, Teunissen CE, Shobin E, Vanderstichele H, Weiner MW, Wilson D, Hansson O. Acceptable performance of blood biomarker tests of amyloid pathology – recommendations from the Global CEO Initiative on Alzheimer’s Disease. Nat Rev Neurol. 2024 Jul;20(7):426-439. doi: 10.1038/s41582-024-00977-5. Epub 2024 Jun 12. PMID: 38866966.
See related video: CEOi BBM Workgroup, Suzanne Schindler feature
Using Alzheimer’s disease blood tests to accelerate clinical trial enrollment
April 1, 2023
Schindler SE, Li Y, Li M, Despotis A, Park E, Vittert L, Hamilton BH, Womack KB, Saef B, Holtzman DM, Morris JC, Bateman RJ, Gupta MR. Using Alzheimer’s disease blood tests to accelerate clinical trial enrollment. Alzheimers Dement. 2023 Apr;19(4):1175-1183. doi: 10.1002/alz.12754. Epub 2022 Aug 7. PMID: 35934777; PMCID: PMC9902574.
CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
March 13, 2023
Barthélemy NR, Saef B, Li Y, Gordon BA, He Y, Horie K, Stomrud E, Salvadó G, Janelidze S, Sato C, Ovod V, Henson RL, Fagan AM, Benzinger TLS, Xiong C, Morris JC, Hansson O, Bateman RJ, Schindler SE. CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease. Nat Aging. 2023 Apr;3(4):391-401. doi: 10.1038/s43587-023-00380-7. Epub 2023 Mar 13. PMID: 37117788; PMCID: PMC10154225.
Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40
March 2, 2023
Wisch JK, Gordon BA, Boerwinkle AH, Luckett PH, Bollinger JG, Ovod V, Li Y, Henson RL, West T, Meyer MR, Kirmess KM, Benzinger TLS, Fagan AM, Morris JC, Bateman RJ, Ances BM, Schindler SE. Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40. Alzheimers Dement (Amst). 2023 Mar 2;15(1):e12405. doi: 10.1002/dad2.12405. PMID: 36874595; PMCID: PMC9980305.
Comparison of plasma and CSF biomarkers in predicting cognitive decline
November 1, 2022
Aschenbrenner AJ, Li Y, Henson RL, Volluz K, Hassenstab J, Verghese P, West T, Meyer MR, Kirmess KM, Fagan AM, Xiong C, Holtzman D, Morris JC, Bateman RJ, Schindler SE. Comparison of plasma and CSF biomarkers in predicting cognitive decline. Ann Clin Transl Neurol. 2022 Nov;9(11):1739-1751. doi: 10.1002/acn3.51670. Epub 2022 Oct 2. PMID: 36183195; PMCID: PMC9639639.
Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light
July 19, 2022
Schindler SE, Karikari TK, Ashton NJ, Henson RL, Yarasheski KE, West T, Meyer MR, Kirmess KM, Li Y, Saef B, Moulder KL, Bradford D, Fagan AM, Gordon BA, Benzinger TLS, Balls-Berry J, Bateman RJ, Xiong C, Zetterberg H, Blennow K, Morris JC. Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light. Neurology. 2022 Jul 19;99(3):e245-e257. doi: 10.1212/WNL.0000000000200358. Epub 2022 Apr 21. PMID: 35450967; PMCID: PMC9302933.
Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET
November 2, 2021
Schindler SE, Li Y, Buckles VD, Gordon BA, Benzinger TLS, Wang G, Coble D, Klunk WE, Fagan AM, Holtzman DM, Bateman RJ, Morris JC, Xiong C. Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. Neurology. 2021 Nov 2;97(18):e1823-e1834. doi: 10.1212/WNL.0000000000012775. Epub 2021 Sep 9. PMID: 34504028; PMCID: PMC8610624.
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
October 22, 2019
Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C, Fagan AM, Bateman RJ. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019 Oct 22;93(17):e1647-e1659. doi: 10.1212/WNL.0000000000008081. Epub 2019 Aug 1. PMID: 31371569; PMCID: PMC6946467.
Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer’s disease
May 1, 2019
Schindler SE, Li Y, Todd KW, Herries EM, Henson RL, Gray JD, Wang G, Graham DL, Shaw LM, Trojanowski JQ, Hassenstab JJ, Benzinger TLS, Cruchaga C, Jucker M, Levin J, Chhatwal JP, Noble JM, Ringman JM, Graff-Radford NR, Holtzman DM, Ladenson JH, Morris JC, Bateman RJ, Xiong C, Fagan AM; Dominantly Inherited Alzheimer Network. Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer’s disease. Alzheimers Dement. 2019 May;15(5):655-665. doi: 10.1016/j.jalz.2018.12.019. Epub 2019 Mar 4. PMID: 30846386; PMCID: PMC6511459.
Recent publications
- Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures across the Alzheimer disease continuumFundació ACE Alzheimer Center Barcelona (FACE), Barcelona-1, Stanford Alzheimer Disease Research Center (Stanford ADRC), Knight Alzheimer Disease Research Center (Knight ADRC) & Alzheimer Disease Neuroimaging Initiative (ADNI), May 7 2025, In: Neuron. 113, 9, p. 1363-1379.e9Research output: Contribution to journal › Article › peer-review
- Associations of Cerebrospinal Fluid Orexin-A, Alzheimer Disease Biomarkers, and Cognitive PerformanceLu, R., Shah, K., Toedebusch, C. D., Hess, A., Richardson, R., Mignot, E., Schindler, S. E., Benzinger, T. L. S., Flores, S., Hassenstab, J., Xiong, C., Morris, J. C., Holtzman, D. M. & Lucey, B. P., Apr 2025, In: Annals of Clinical and Translational Neurology. 12, 4, p. 780-791 12 p.Research output: Contribution to journal › Article › peer-review
- The CentiMarker project: Standardizing quantitative Alzheimer's disease fluid biomarkers for biologic interpretationthe Alzheimer's Disease Neuroimaging Initiative, Apr 2025, In: Alzheimer's and Dementia. 21, 4, e14587.Research output: Contribution to journal › Article › peer-review
- Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's diseaseLeuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., La Joie, R., Rabinovici, G. D., Franzmeier, N., Johnson, K., Barkhof, F., Shaw, L. M., Arkhipenko, A., Schindler, S. E., Honig, L. S., Moscoso Rial, A., Schöll, M., Zetterberg, H., Blennow, K., Hansson, O. & Farrar, G., Mar 2025, In: Alzheimer's and Dementia. 21, 3, e14528.Research output: Contribution to journal › Review article › peer-review
- Benchmarking of a multi-biomarker low-volume panel for Alzheimer's disease and related dementia researchIbanez, L., Liu, M., Beric, A., Timsina, J., Kohlfeld, P., Bergmann, K., Lowery, J., Sykora, N., Sanchez-Montejo, B., Brock, W., Budde, J. P., Bateman, R. J., Barthelemy, N., Schindler, S. E., Holtzman, D. M., Benzinger, T. L. S., Xiong, C., Tarawneh, R., Moulder, K. & Morris, J. C. & 2 others, Sung, Y. J. & Cruchaga, C., Feb 2025, In: Alzheimer's and Dementia. 21, 2, e14413.Research output: Contribution to journal › Article › peer-review
- A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker testsWarmenhoven, N., Salvadó, G., Janelidze, S., Mattsson-Carlgren, N., Bali, D., Orduña Dolado, A., Kolb, H., Triana-Baltzer, G., Barthélemy, N. R., Schindler, S. E., Aschenbrenner, A. J., Raji, C. A., Benzinger, T. L. S., Morris, J. C., Ibanez, L., Timsina, J., Cruchaga, C., Bateman, R. J., Ashton, N. & Arslan, B. & 4 others, Zetterberg, H., Blennow, K., Binette, A. P. & Hansson, O., Feb 1 2025, In: Brain. 148, 2, p. 416-431 16 p.Research output: Contribution to journal › Article › peer-review
- Anti-amyloid treatments: Why we think they are worth itSchindler, S. E., Musiek, E. S. & Morris, J. C., Jan 1 2025, In: Alzheimer's and Dementia: Translational Research and Clinical Interventions. 11, 1, e70055.Research output: Contribution to journal › Comment/debate
- Assessing the clinical meaningfulness of slowing CDR-SB progression with disease-modifying therapies for Alzheimer's diseaseHartz, S. M., Schindler, S., Streitz, M. L., Moulder, K. L., Mozersky, J., Wang, G., Xiong, C. & Morris, J., Jan 1 2025, In: Alzheimer's and Dementia: Translational Research and Clinical Interventions. 11, 1, e70033.Research output: Contribution to journal › Article › peer-review
- Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s diseaseHorie, K., Salvadó, G., Koppisetti, R. K., Janelidze, S., Barthélemy, N. R., He, Y., Sato, C., Gordon, B., Jiang, H., Benzinger, T. L. S., Stomrud, E., Holtzman, D., Mattsson-Carlgren, N., Morris, J., Palmqvist, S., Ossenkoppele, R., Schindler, S., Hansson, O. & Bateman, R., 2025, (Accepted/In press) In: Nature medicine. e76494.Research output: Contribution to journal › Article › peer-review
- Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trialsPREVENT-AD Research Group, 2025, (Accepted/In press) In: Nature Aging. 2311.Research output: Contribution to journal › Article › peer-review